Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Among people with low levels of LDL cholesterol—even those who achieve very large absolute reductions with statin therapy—higher levels of lipoprotein(a) are associated with an increased risk of ...